CN107708689A - 用作抗生素的Korormicin衍生物 - Google Patents

用作抗生素的Korormicin衍生物 Download PDF

Info

Publication number
CN107708689A
CN107708689A CN201680033925.3A CN201680033925A CN107708689A CN 107708689 A CN107708689 A CN 107708689A CN 201680033925 A CN201680033925 A CN 201680033925A CN 107708689 A CN107708689 A CN 107708689A
Authority
CN
China
Prior art keywords
compound
vibrio
infection
group
chlamydia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680033925.3A
Other languages
English (en)
Chinese (zh)
Inventor
帕维尔·迪布韦
埃莱娜·迪布韦
格兰特·皮尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202310483500.4A priority Critical patent/CN116574132A/zh
Publication of CN107708689A publication Critical patent/CN107708689A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201680033925.3A 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物 Pending CN107708689A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310483500.4A CN116574132A (zh) 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151902P 2015-04-23 2015-04-23
US62/151,902 2015-04-23
PCT/CA2016/050470 WO2016168938A1 (en) 2015-04-23 2016-04-22 Derivatives of korormicin useful as antibiotics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310483500.4A Division CN116574132A (zh) 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物

Publications (1)

Publication Number Publication Date
CN107708689A true CN107708689A (zh) 2018-02-16

Family

ID=57142747

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680033925.3A Pending CN107708689A (zh) 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物
CN202310483500.4A Pending CN116574132A (zh) 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310483500.4A Pending CN116574132A (zh) 2015-04-23 2016-04-22 用作抗生素的Korormicin衍生物

Country Status (8)

Country Link
US (5) US10166213B2 (cg-RX-API-DMAC7.html)
EP (1) EP3285762A4 (cg-RX-API-DMAC7.html)
JP (3) JP6842089B2 (cg-RX-API-DMAC7.html)
CN (2) CN107708689A (cg-RX-API-DMAC7.html)
AU (4) AU2016253429B2 (cg-RX-API-DMAC7.html)
CA (1) CA2983460A1 (cg-RX-API-DMAC7.html)
IL (2) IL310102A (cg-RX-API-DMAC7.html)
WO (1) WO2016168938A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116617231A (zh) * 2023-06-12 2023-08-22 沈阳药科大学 2-氨基萘嵌间二氮杂苯氢溴化物增强对革兰氏阴性菌杀菌作用的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3285762A4 (en) * 2015-04-23 2019-02-06 Dibrov, Pavel DERIVATIVES OF KORORMICIN AS ANTIBIOTICS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000336088A (ja) * 1999-05-27 2000-12-05 Marine Biotechnol Inst Co Ltd 新規化学物質F420m類縁体
JP2001010908A (ja) * 1999-06-28 2001-01-16 Marine Biotechnol Inst Co Ltd 防汚剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2315489A (en) * 1996-07-17 1998-02-04 Merck & Co Inc Antifungal agent
JP3905604B2 (ja) * 1997-03-04 2007-04-18 株式会社海洋バイオテクノロジー研究所 新規化学物質コロールミシン
JP2000281670A (ja) 1999-03-26 2000-10-10 Marine Biotechnol Inst Co Ltd 新規コロールミシン合成中間体及び製造法
JP2003061645A (ja) 2001-08-23 2003-03-04 Marine Biotechnol Inst Co Ltd 海洋細菌の選択培地
WO2008116029A1 (en) * 2007-03-19 2008-09-25 Wisconsin Alumni Research Foundation Modulation of bacterial quorum sensing with synthetic ligands
WO2011001419A1 (en) * 2009-07-03 2011-01-06 National Institute For Biotechnology In The Negev Covalent inhibition of bacterial quorum sensing
EP3285762A4 (en) * 2015-04-23 2019-02-06 Dibrov, Pavel DERIVATIVES OF KORORMICIN AS ANTIBIOTICS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000336088A (ja) * 1999-05-27 2000-12-05 Marine Biotechnol Inst Co Ltd 新規化学物質F420m類縁体
JP2001010908A (ja) * 1999-06-28 2001-01-16 Marine Biotechnol Inst Co Ltd 防汚剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HISATOSHI UEHARA ET AL: "The absolute configuration and total synthesis of korormicin", 《TETRAHEDRON LETTERS》 *
JAN TEBBEN ET AL: "A Coralline Algal-Associated Bacterium, Pseudoalteromonas Strain J010, Yields Five New Korormicins and a Bromopyrrole", 《MAR.DRUGS》 *
KAZUHIRO YOSHIKAWA ET AL: "Korormicin, a Novel Antibiotic Specifically Active against Marine Gram-negative Produced by a Marine Bacterium", 《THE JOURNAL OF ANTIBIOTICS》 *
KAZUHIRO YOSHIKAWA ET AL: "Korormicin, an Antibiotic Specific for Gram-negative Marine Bacteria,Strongly Inhibits the Respiratory Chain-linked Na+ -Translocating NADH:Quinone Reductase from the Marine vibrio alginolyticus", 《THE JOURNAL OF ANTIBIOTICS》 *
KAZUHIRO YOSHIKAWA ET AL: "Planar Structure and Antibacterial Activity of Korormicin Derivatives Isolated from Pseudoalteromonas sp. F-420", 《THE JOURNAL OF ANTIBIOTICS》 *
YUICHI KOBAYASHI ET AL: "Determination of the stereoisomer of korormicin from eight possible stereoisomers by total synthesis", 《TETRAHEDRON LETTERS》 *
YUICHI KOBAYASHI ET AL: "Total Synthesis of Korormicin", 《EUROPEN JOURNAL OF ORGANIC CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116617231A (zh) * 2023-06-12 2023-08-22 沈阳药科大学 2-氨基萘嵌间二氮杂苯氢溴化物增强对革兰氏阴性菌杀菌作用的应用

Also Published As

Publication number Publication date
US20200345682A1 (en) 2020-11-05
IL255182B2 (en) 2024-06-01
AU2022204906B2 (en) 2024-03-28
AU2022204906A1 (en) 2022-07-28
AU2019202254A1 (en) 2019-05-02
JP2018513194A (ja) 2018-05-24
JP7121225B2 (ja) 2022-08-18
US20190083450A1 (en) 2019-03-21
IL255182A0 (en) 2017-12-31
AU2020267205B2 (en) 2022-04-14
US10166213B2 (en) 2019-01-01
AU2016253429A1 (en) 2017-12-07
US10744111B2 (en) 2020-08-18
US12029716B2 (en) 2024-07-09
IL310102A (en) 2024-03-01
CA2983460A1 (en) 2016-10-27
IL255182B1 (en) 2024-02-01
EP3285762A4 (en) 2019-02-06
AU2019202254B2 (en) 2020-08-13
CN116574132A (zh) 2023-08-11
US20220257555A1 (en) 2022-08-18
US20180064680A1 (en) 2018-03-08
AU2016253429B2 (en) 2019-01-03
WO2016168938A1 (en) 2016-10-27
JP2022122857A (ja) 2022-08-23
EP3285762A1 (en) 2018-02-28
JP6842089B2 (ja) 2021-03-17
AU2020267205A1 (en) 2020-12-10
US20240358670A1 (en) 2024-10-31
US11324716B2 (en) 2022-05-10
JP2021073278A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
Qin et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics
Denis et al. Targeting Type IV pili as an antivirulence strategy against invasive meningococcal disease
Li et al. Lactobacillus rhamnosus GR-1 prevents Escherichia coli-induced apoptosis through PINK1/Parkin-mediated mitophagy in bovine mastitis
Wiles et al. Inactivation of host Akt/protein kinase B signaling by bacterial pore-forming toxins
US20240358670A1 (en) Derivatives of korormicin useful as antibiotics
Sousa et al. A comprehensive review of therapeutic approaches available for the treatment of cholera
JP2013523111A (ja) 転写因子デコイ
JP2007521239A (ja) 抗菌組成物及び使用方法
CA2413284A1 (fr) Utilisation d'acides en c4-c10 pour la prevention des infections a bacteries a gram negatif
JP6590924B2 (ja) 微生物感染を治療するための相乗的組成物
Peng et al. Plant phenolic acids enhance antibiotic efficacy against multidrug-resistant extraintestinal pathogenic Escherichia coli
Pointon Copper homeostasis and Salmonella pathogenicity: Interplay with resistance to nitrosative stress
Patil A New Class of Antibiotic That Prevents Drug Tolerance, Persistence, and Resistance By Controlling Emergence of Phenotypes
Wang et al. Prim-O-glucosylcimifugin targets Staphylococcus aureus caseinolytic protease P to inhibit α-hemolysin expression and promote healing of MRSA-induced diabetic skin infections
CN119837893A (zh) 5-氟-2′-脱氧胞苷在制备抗菌药物中的用途
Yi Deciphering the Transport Mechanism of Pseudomonas Quinolone Signal Across the Cell Envelope of Pseudomonas Aeruginosa
Krahn Chromosomal Determinants of Aminoglycoside Resistance in Pseudomonas aeruginosa
Gussmann Long-term effects of amino acids on chlamydia infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180216